Shinichi Taguchi

Dr. Shinichi Taguchi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2018 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
STShinichi Taguchi
Shinichi Taguchi

1 January 2015 in Annals of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
STShinichi Taguchi
Shinichi Taguchi
Primary cardiac solitary fibrous tumors were reviewed. They are classified as pericardial tumors. Their incidences are very rare. Only 16 cases were reported in the literature. Basically, surgical treatments are performed. Their prognoses are generally good, although malignant cases are also reported.

2 April 2022 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
HHHiroshi Hashimoto
Hiroshi Hashimoto
KKKazuyuki Komori
Kazuyuki Komori
KKKoji Kameda
Koji Kameda
STShinichi Taguchi
Shinichi Taguchi
YOYuichi Ozeki
Yuichi Ozeki
Background: Anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the therapy of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement. However, its treatment after failure of initial ALK–TKI therapy remains controversial. Case presentation: A 47-year-old woman with a hemosputum was diagnosed with adenocarcinoma of the left lung (cT2bN3M0, stage IIIB). Gene mutation analysis indicated positive ALK translocation. Alectinib was selected as the first-line treatment. Although the treatment effect was determined as a partial response, the main tumor regrew. Alectinib was discontinued, and salvage surgery was performed without causing morbidity. The pathological diagnosis was pleomorphic carcinoma without lymph node metastasis (yp-T2bN0). After surgery, lorlatinib was administered as the second-line treatment for 8 months until the patient could not tolerate continuation. Computed tomography scan revealed no lung cancer recurrence 14 months after discontinuation. Conclusions: Our experience with this case suggests that salvage surgery after alectinib treatment followed by lorlatinib therapy may be effective for initially unresectable ALK-positive NSCLC.


1 January 2019 in International Journal of Case Reports and Images
Verified
Journal Article
Open access
HHHiroshi Hashimoto
Hiroshi Hashimoto
YOYuichi Ozeki
Yuichi Ozeki
KKKoji Kameda
Koji Kameda
HSHideyuki Shimazaki
Hideyuki Shimazaki
STShinichi Taguchi
Shinichi Taguchi
Introduction: Primary thymic adenocarcinoma is a notably rare neoplasm. Here, we described a case of non-papillary thymic adenocarcinoma that was comparable to adenocarcinoma not otherwise specified (NOS) according to the recent WHO classification. Case Report: A 69-year-old woman presented to our hospital with an anterior mediastinal tumor. Thymothymectomy was performed. Histological examination revealed dense proliferation of irregular tubular and partially solid atypical cells with fibrous stroma. Based on pathological and immunohistochemical findings, and the absence of primary tumors in other sites, a diagnosis of primary thymic adenocarcinoma NOS was established. Recently, enteric-type adenocarcinoma was detected in a subset of adenocarcinoma NOS, but the current case was not of this type. The patient was alive without any sign of recurrence 30 months postoperatively. Conclusion: Our case report suggests that some adenocarcinomas NOS are not enteric and that this finding should be further evaluated.